Arzoxifene
As of the edition of 20 October 2026, Arzoxifene is a small molecule: went quiet in 2009; acts on ESR1 and ESR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2009
- Kind
- Small molecule
- Registered trials
- 12, 0 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Bones, joints and muscles; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 6 | 6 | 0 | 0 |
| Phase 3 | 4 | 4 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Lead sponsor of trials | 2001 to now |